Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement†‡
Authors:
- Richard S. LegroRLRichard S. Legro
- Xiaoke WuXWXiaoke Wu
- Cynthia FarquharCFCynthia Farquhar
- Craig NiederbergerCNCraig Niederberger
- Ernest H.Y. NgENErnest H.Y. Ng
- Stefano PalombaSPStefano Palomba
- Arcispedale S. MariaAMArcispedale S. Maria
- Reggio EmiliaREReggio Emilia
Open Access
- 10 October 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 29 (10) , 2075-2082
Abstract
Clinical trials testing infertility treatments often do not report on the major outcomes of interest to patients and clinicians and the public (such as live birth) nor on the harms, including maternal risks during pregnancy and fetal anomalies. This is complicated by the multiple participants in infertility trials which may include a woman (mother), a man (father), and result in a third individual if successful, their offspring (child), who is also the desired outcome of treatment. The primary outcome of interest and many adverse events occur after cessation of infertility treatment and during pregnancy and the puerperium, which create a unique burden of follow-up for clinical trial investigators and participants. In 2013, because of the inconsistencies in trial reporting and the unique aspects of infertility trials not adequately addressed by existing Consolidated Standards of Reporting Trials (CONSORT) statements, we convened a consensus conference in Harbin, China, with the aim of planning modifications to the CONSORT checklist to improve the quality of reporting of clinical trials testing infertility treatment. The consensus group recommended that the preferred primary outcome of all infertility trials is live birth (defined as any delivery of a live infant ≥20 weeks gestations) or cumulative live birth, defined as the live birth per women over a defined time period (or number of treatment cycles). In addition, harms to all participants should be systematically collected and reported, including during the intervention, any resulting pregnancy, and during the neonatal period. Routine information should be collected and reported on both male and female participants in the trial. We propose to track the change in quality that these guidelines may produce in published trials testing infertility treatments. Our ultimate goal is to increase the transparency of benefits and risks of infertility treatments to provide better medical care to affected individuals and couples.Keywords
This publication has 24 references indexed in Scilit:
- Incomplete and inconsistent reporting of maternal and fetal outcomes in infertility treatment trialsFertility and Sterility, 2011
- Measuring outcomes in fertility trials: can we rely on clinical pregnancy rates?Fertility and Sterility, 2010
- Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT StatementPLOS Medicine, 2010
- CONSORT 2010 StatementObstetrics & Gynecology, 2010
- International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in PregnancyDiabetes Care, 2010
- Guidance for Developers of Health Research Reporting GuidelinesPLOS Medicine, 2010
- Ovarian hyperstimulation syndromeFertility and Sterility, 2006
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2006
- Ovarian hyperstimulation syndromeFertility and Sterility, 2003
- A practical classification of newborn infants by weight and gestational ageThe Journal of Pediatrics, 1967